Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 12OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 74Leucovorin 48Oxaliplatin 44Cisplatin 40Capecitabine 39Gemcitabine 37Radiotherapy 30Irinotecan 28Cetuximab 21Paclitaxel 15Bevacizumab 12Docetaxel 10Taxes 9durvalumab 8dehydroftorafur 8Surgical Procedures, Operative 8Mitomycin 8Specimen Handling 7Platinum 7Folfox protocol 7Carboplatin 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7S 1 (combination) 6Panitumumab 6Watchful Waiting 5Imatinib Mesylate 5Gene Expression Profiling 5Epirubicin 5tremelimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × brivanib × Gastrointestinal × Clear all
NCT00640471 2023-08-04

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Canadian Cancer Trials Group

Phase 3 Completed
750 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡